UBS Group AG Purchases 2,654,315 Shares of Lexicon Pharmaceuticals, Inc. $LXRX

UBS Group AG lifted its position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 752.1% during the 4th quarter, Holdings Channel reports. The firm owned 3,007,237 shares of the biopharmaceutical company’s stock after acquiring an additional 2,654,315 shares during the period. UBS Group AG’s holdings in Lexicon Pharmaceuticals were worth $3,458,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Bank of America Corp DE grew its holdings in shares of Lexicon Pharmaceuticals by 80.1% in the third quarter. Bank of America Corp DE now owns 57,804 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 25,707 shares during the last quarter. Vermillion & White Wealth Management Group LLC grew its holdings in shares of Lexicon Pharmaceuticals by 400.0% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 26,000 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in shares of Lexicon Pharmaceuticals in the second quarter worth approximately $26,000. Cerity Partners LLC grew its holdings in shares of Lexicon Pharmaceuticals by 21.1% in the second quarter. Cerity Partners LLC now owns 206,279 shares of the biopharmaceutical company’s stock worth $195,000 after purchasing an additional 35,892 shares during the last quarter. Finally, XTX Topco Ltd grew its holdings in shares of Lexicon Pharmaceuticals by 431.4% in the second quarter. XTX Topco Ltd now owns 66,276 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 53,805 shares during the last quarter. Institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Stock Performance

Shares of Lexicon Pharmaceuticals stock opened at $2.16 on Monday. The company has a current ratio of 18.80, a quick ratio of 18.77 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $959.46 million, a P/E ratio of -30.85 and a beta of 0.97. The business has a fifty day simple moving average of $1.80 and a two-hundred day simple moving average of $1.52. Lexicon Pharmaceuticals, Inc. has a 12 month low of $0.62 and a 12 month high of $2.53.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $0.00 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.04. The business had revenue of $21.10 million during the quarter, compared to analyst estimates of $9.79 million. Lexicon Pharmaceuticals had a negative return on equity of 18.64% and a negative net margin of 37.46%. On average, equities analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on LXRX. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Lexicon Pharmaceuticals in a report on Monday, March 23rd. Citigroup lifted their price target on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the company a “buy” rating in a report on Monday, May 11th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Lexicon Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $4.55.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.